A Double-Blind, Randomized, Parallel, Two-Arm Phase H Trial of BMS-690514 versus Erlotinib in Previous Chemotherapy-Treated Non-small Cell Lung Cancer (NSCLC) Patients: A Safety Review

被引：0
|
作者：
Sbar, E. [1 ]
Besse, B. [2 ]
Felip, E. [3 ]
Shaw, A. [4 ]
Ahn, M. [5 ]
Salvati, M. [1 ]
Bhagavatheeswaran, P. [1 ]
Soria, J. [2 ]
机构：
[1] Bristol Myers Squibb Co, Princeton, NJ USA
[2] Inst Gustave Roussy, Villejuif, France
[3] Hosp Valle De Hebron, Barcelona, Spain
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
[5] Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S538 / S539
页数：2
相关论文
共 50 条
  • [31] A phase III, randomized, double-blind, placebo-controlled study of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC)
    Sandler, A.
    Schiller, J. H.
    Hirsh, V.
    Sequist, L. V.
    Soria, J.
    Von Pawel, J.
    Wang, Q.
    Pande, A. U.
    Schwartz, B. E.
    Garmey, E. G.
    Gorbatchevsky, I.
    Scagliotti, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT)
    Boyer, M. J.
    Blackhall, F. H.
    Park, K.
    Barrios, C. H.
    Krzakowski, M. J.
    Taylor, I.
    Liang, J. Q.
    Denis, L. J.
    O'Connell, J. P.
    Ramalingam, S. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [33] Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial
    Rosell, R.
    Gervais, R.
    Vergnenegre, A.
    Massuti, B.
    Felip, E.
    Cardenal, F.
    Garcia Gomez, R.
    Pallares, C.
    Sanchez, J. M.
    Porta, R.
    Cobo, M.
    Di Seri, M.
    Garrido Lopez, P.
    Insa, A.
    De Marinis, F.
    Corre, R.
    Carreras, M.
    Carcereny, E.
    Taron, M.
    Paz-Ares, L. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer (NSCLC)
    Karp, D. D.
    Lee, S. J.
    Wright, G. L. Shaw
    Johnson, D. H.
    Johnston, M. R.
    Goodman, G. E.
    Clamon, G. H.
    Okawara, G. S.
    Marks, R.
    Ruckdeschel, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [35] Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy: preliminary results
    Ross, HJ
    Blumenschein, GR
    Dowlati, A
    Aisner, J
    Rigas, JR
    Stanislaus, M
    Leopold, LH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 645S - 645S
  • [36] Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial
    Ramalingam, Suresh S.
    Jaenne, Pasi A.
    Mok, Tony
    O'Byrne, Kenneth
    Boyer, Michael J.
    Von Pawel, Joachim
    Pluzanski, Adam
    Shtivelband, Mikhail
    Iglesias Docampo, Lara
    Bennouna, Jaafar
    Zhang, Hui
    Liang, Jane Q.
    Doherty, Jim P.
    Taylor, Ian
    Mather, Cecile B.
    Goldberg, Zelanna
    O'Connell, Joseph
    Paz-Ares, Luis
    LANCET ONCOLOGY, 2014, 15 (12): : 1369 - 1378
  • [37] OVERALL SURVIVAL (OS) RESULTS OF A RANDOMIZED PHASE 2 TRIAL OF PF299804 VERSUS ERLOTINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AFTER FAILURE OF CHEMOTHERAPY
    Boyer, Michael
    Blackhall, Fiona H.
    Barrios, Carlos H.
    Frank, Richard C.
    Heo, Deo Seog
    Park, Keunchil
    Rosell, Rafael
    Talbot, Denis C.
    Taylor, Ian C.
    Liang, Jane
    Campbell, Alicyn K.
    O'Connell, Joseph
    Ramalingam, Suresh
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S318 - S319
  • [38] Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer
    Kunikane H.
    Watanabe K.
    Fukuoka M.
    Saijo N.
    Furuse K.
    Ikegami H.
    Ariyoshi Y.
    Kishimoto S.
    International Journal of Clinical Oncology, 2001, 6 (6) : 296 - 301
  • [39] MARQUEE: A randomized, double-blind, placebo-controlled, phase 3 trial of tivantinib (ARQ 197) plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, non-squamous, non-small-cell lung cancer (NSCLC)
    Scagliotti, G.
    Novello, S.
    Ramlau, R.
    Favaretto, A.
    Barlesi, F.
    Akerley, W.
    Von Pawel, J.
    Shuster, D.
    Schwartz, B.
    Sandler, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S798 - S799
  • [40] EFFICACY ANALYSIS FOR MOLECULAR SUBGROUPS IN MARQUEE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF TIVANTINIB (ARQ 197) PLUS ERLOTINIB VERSUS PLACEBO PLUS ERLOTINIB IN PREVIOUSLY TREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC, NON-SQUAMOUS, NON-SMALL CELL LUNG CANCER (NSCLC)
    Novello, Silvia
    Scagliotti, Giorgio
    Ramlau, Rodryg
    Favaretto, Adolfo
    Barlesi, Fabrice
    Akerley, Wallace
    Von Pawel, Joachim
    Orlov, Sergey
    Spigel, David R.
    Santoro, Armando
    Shepherd, Frances
    Hirsh, Vera
    Sequist, Lecia V.
    Shuster, Dale
    Zahir, Hamim
    Wang, Qiang
    Schwartz, Brian
    Von Roemeling, Reinhard
    Sandler, Allan B.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S901 - S902
12345